Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Surging
PumaBiotech (@pumabiotech) / Twitter
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology Profile | FDA Health News
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire